Eukaryotic Cell Patents (Class 424/93.21)
-
Patent number: 11952408Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: September 28, 2018Date of Patent: April 9, 2024Assignees: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron Brandt, Brian Belmont, Christopher Borges, Stephen Michael Burleigh, Alexandra Croft, Stephen Jacob Goldfless, David Jeffrey Huss, Yue Jiang, Timothy G. Johnstone, David Koppstein, Hieu Nguyen, Christopher Heath Nye, Haley Peper, Blythe D. Sather, Sonia Timberlake, Dean Y. Toy, Queenie Vong, Gordon Grant Welstead, James Sissons
-
Patent number: 11951185Abstract: Disclosed herein are RNA polynucleotides comprising a 5? Cap, a 5? UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.Type: GrantFiled: December 30, 2021Date of Patent: April 9, 2024Assignee: BioNTech SEInventors: Ugur Sahin, Gábor Boros, Azita Josefine Mahiny, Jonas Reinholz, Katalin Karikó
-
Patent number: 11945850Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: September 16, 2019Date of Patent: April 2, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
-
Patent number: 11938153Abstract: The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides chimeric antigen receptor (CAR) T cells that are modified to maintain functionality under conditions in which unmodified CAR T cells display exhaustion. Compositions and methods disclosed herein find use in inhibiting or reversing CAR T cell exhaustion (e.g., by modulating CAR surface expression) thereby enhancing CAR T cell function. Compositions and methods of the invention fmd use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.Type: GrantFiled: March 30, 2018Date of Patent: March 26, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Rachel Lynn, Crystal Mackall, Tom J. Wandless, Evan Weber
-
Patent number: 11918822Abstract: The present invention relates to compositions and methods configured to deliver a stimulus (e.g., a therapeutic agent or a therapeutically beneficial signal) to a cell, tissue, organ, or organism. The stimulus is applied at least twice, and the first and second applications are separated by a rest period in which no further stimulus is actively applied. The rest period is of a duration (e.g., about 1-6 hours) sufficient to provoke an enhanced response to the second stimulus.Type: GrantFiled: October 19, 2022Date of Patent: March 5, 2024Assignees: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Clinton Rubin, Janet Rubin
-
Patent number: 11905328Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.Type: GrantFiled: July 13, 2018Date of Patent: February 20, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Martin Hofmann, Felix Unverdorben, Sebastian Bunk, Dominik Maurer
-
Patent number: 11905336Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.Type: GrantFiled: September 10, 2019Date of Patent: February 20, 2024Assignee: Lung Therapeutics, Inc.Inventors: Dale Christensen, John J. Koleng
-
Patent number: 11905514Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: February 20, 2024Assignee: GLAXOSMITHKLINE BIOLOGICAL SAInventor: Andrew Geall
-
Patent number: 11891608Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: February 6, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Patent number: 11883433Abstract: Provided is an anti-mesothelin chimeric antigen receptor that specifically binds to mesothelin. The anti-mesothelin chimeric antigen receptor according to an aspect exhibits a specific binding ability for mesothelin, and thus, may be useful for preventing or treating cancer in which mesothelin is overexpressed.Type: GrantFiled: May 25, 2022Date of Patent: January 30, 2024Assignee: CELLENGENE INC.Inventors: Jae Hyung An, Na Kyung Han
-
Patent number: 11866731Abstract: Provided are modified immune cells including tumor infiltrating lymphocyte (TIL) or B cells, a composition comprising the immune cells, and a method of treating neoplastic or cancer conditions comprising administering to a subject the immune cells.Type: GrantFiled: November 12, 2018Date of Patent: January 9, 2024Assignee: CHINEO MEDICAL TECHNOLOGY CO., LTDInventor: Weiyue Gu
-
Patent number: 11851491Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.Type: GrantFiled: November 22, 2017Date of Patent: December 26, 2023Assignee: TCR2 THERAPEUTICS INC.Inventors: Patrick Baeuerle, Robert Hofmeister
-
Patent number: 11850288Abstract: A gene and cell therapy using a cell fusion technology is proposed. Cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.Type: GrantFiled: June 30, 2020Date of Patent: December 26, 2023Assignee: CURAMYS INC.Inventors: Jung-Joon Sung, Seung-Yong Seong, Hee-Woo Lee, Ki Yoon Kim
-
Patent number: 11851653Abstract: The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.Type: GrantFiled: December 1, 2016Date of Patent: December 26, 2023Assignee: CRISPR THERAPEUTICS AGInventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Jeffrey Li, Ante Sven Lundberg, Matthias Johannes John, Jeffrey William Stebbins, Thao Thi Nguyen
-
Patent number: 11851660Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: December 26, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Patent number: 11845965Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.Type: GrantFiled: January 9, 2020Date of Patent: December 19, 2023Assignee: Sangamo Therapeutics, Inc.Inventors: Jeffrey C. Miller, Edward J. Rebar
-
Patent number: 11845925Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: December 19, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Patent number: 11827705Abstract: The present invention includes compositions and methods for an HLA-A2 specific chimeric antigen receptor (CAR). In certain embodiments the HLA-A2 specific CAR is expressed on a T regulatory cell. In certain embodiments, the HLA-A2 specific CAR protects transplanted tissue from rejection.Type: GrantFiled: March 27, 2018Date of Patent: November 28, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: James L. Riley, Gavin Ellis
-
Patent number: 11815514Abstract: Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS.Type: GrantFiled: December 2, 2016Date of Patent: November 14, 2023Assignees: Juno Therapeutics, Inc., Fred Hutchinson Cancer Research CenterInventors: He Li, Mark J. Gilbert, David Maloney, Stanley R. Riddell, Cameron J. Turtle
-
Patent number: 11795474Abstract: The invention relates to retroviral producer cell comprising nucleic acid sequences encoding: gag and pol proteins; envelope protein or a functional substitute thereof; amplifiable selection marker; and the RNA genome of the retroviral vector particle, wherein said nucleic acid sequences are all integrated at a single locus within the retroviral producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that said nucleic acid vector comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof. The nucleic acid vector additionally comprises nucleic acid sequences encoding an amplifiable selection marker. The invention also relates to uses and methods using said nucleic acid vector in order to produce stable retroviral packaging and producer cell lines.Type: GrantFiled: April 18, 2018Date of Patent: October 24, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventor: Conrad Vink
-
Patent number: 11793888Abstract: Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.Type: GrantFiled: March 30, 2020Date of Patent: October 24, 2023Assignee: Sangamo Therapeutics, Inc.Inventors: Michael C. Holmes, Brigit E. Riley
-
Patent number: 11773395Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: October 3, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Patent number: 11732240Abstract: The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.Type: GrantFiled: July 27, 2017Date of Patent: August 22, 2023Assignee: UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)Inventors: Jeong Beom Kim, Myung Rae Park, Man Sze Wong
-
Patent number: 11717579Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.Type: GrantFiled: March 3, 2017Date of Patent: August 8, 2023Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTONInventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
-
Patent number: 11707488Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.Type: GrantFiled: August 29, 2016Date of Patent: July 25, 2023Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Masayo Yumoto, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
-
Patent number: 11685909Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.Type: GrantFiled: April 8, 2021Date of Patent: June 27, 2023Assignee: The Regents of the University of CaliforniaInventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
-
Patent number: 11649436Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.Type: GrantFiled: December 1, 2017Date of Patent: May 16, 2023Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Tai Gyu Kim, Hyun Jung Sohn, Su Eon Kim
-
Patent number: 11649431Abstract: Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons.Type: GrantFiled: October 23, 2015Date of Patent: May 16, 2023Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, CORNELL UNIVERSITYInventors: Lorenz Studer, Asif M. Maroof, Stewart Anderson
-
Patent number: 11634732Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: GrantFiled: October 15, 2021Date of Patent: April 25, 2023Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Patent number: 11613735Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.Type: GrantFiled: February 4, 2015Date of Patent: March 28, 2023Assignees: BeiHao Stem Cell and Regenerative Medicine Translational Research Institute, Peking University, Beijing Vitalstar Biotechnology Co., Ltd.Inventors: Hongkui Deng, Yuanyuan Du, Yan Shi, Jun Jia, Jinlin Wang, Chengang Xiang, Nan Song, Jun Xu, Ming Yin
-
Patent number: 11607427Abstract: A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.Type: GrantFiled: February 21, 2020Date of Patent: March 21, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Noriyuki Kasahara, Robert H. Schiestl, Katrin Hacke, Akos Szakmary, Gay M. Crooks
-
Patent number: 11596700Abstract: The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.Type: GrantFiled: February 10, 2017Date of Patent: March 7, 2023Assignee: UNIVERSITY OF ROCHESTERInventor: Steven A. Goldman
-
Patent number: 11579141Abstract: The present invention relates to an in vitro method for identifying a skin wound in an individual as being a non-healing skin wound or healing skin wound, in vitro methods for monitoring the healing of a skin wound in an individual, methods for screening for compounds suitable for modulating skin wound healing, as well as kits related thereto.Type: GrantFiled: October 23, 2017Date of Patent: February 14, 2023Assignee: AKRIBES BIOMEDICAL GMBHInventors: Barbara Wolff-Winiski, Anton Stütz, Petra Dörfler
-
Patent number: 11564942Abstract: Disclosed herein are methods for generating universal MHC/HLA-compatible hematopoietic progenitor cells and methods for generating custom patient-specific MHC/HLA-compatible hematopoietic progenitor cells. Compositions comprising the universal and custom hematopoietic progenitor cells and therapeutic applications thereof are also disclosed.Type: GrantFiled: February 17, 2017Date of Patent: January 31, 2023Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: Michael K. Mansour, David B. Sykes, David T. Scadden
-
Patent number: 11560402Abstract: The invention relates to a method for the cleavage of a solid phase-bound polypeptide from the solid phase, the method comprising contacting the solid phase, to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol, at a temperature in the range of about 23° C. to about 29° C.Type: GrantFiled: April 10, 2019Date of Patent: January 24, 2023Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Wolfgang Fiedler, Norbert Pleuss, Bernd Henkel, Manfred Gerken
-
Patent number: 11530252Abstract: Described herein is a chimeric antigen receptor (CAR) platform with the ability to (a) serve as an ON/OFF switch (with the ability for tenability/titrability), (b) sense multiple antigens and perform logic computations, and/or (c) independently regulate multiple signaling pathways. The compositions provided herein permit the degree of control and discrimination necessary to optimize CAR T cell therapy. Also described herein are cells comprising such compositions and the use of these compositions and/or cells in the treatment of cancer.Type: GrantFiled: November 22, 2016Date of Patent: December 20, 2022Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: Wilson W. Wong, Jang Hwan Cho
-
Patent number: 11525004Abstract: Disclosed are compositions and methods for targeted treatment of CD123-expressing cancers. In particular, recombinant antibodies are disclosed that are able to engage T-cells to destroy CD123-expressing malignant cells.Type: GrantFiled: July 18, 2018Date of Patent: December 13, 2022Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventor: Marco L. Davila
-
Patent number: 11517530Abstract: Provided herein are extracellular vesicle (EV) (a.k.a. exosome) compositions for specifically targeting the delivery of a therapeutic agent to particular cells and/or tissues in a subject, as well as methods of making and methods of using said compositions. The compositions and methods disclosed herein are useful for targeted drug delivery in the treatment of diseases in which a cell surface receptor is overexpressed, such as, for example, cancer.Type: GrantFiled: September 25, 2018Date of Patent: December 6, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jing-Hung Wang, Alexis Forterre, A. C. Matin, Alain Delcayre
-
Patent number: 11517590Abstract: In order to improve the efficiency of gene introduction in CAR therapy employing a transposon method, provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (1) a step of preparing non-proliferative cells which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by a treatment for causing the cells to lose their proliferation capability; (2) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (3) a step of mixing the non-proliferative cells prepared by step (1) with the genetically-modified T cells obtained by step (2), and co-culturing the mixed cells while stimulating the mixed cells using an anti-CD3 antibody and anti-CD28 antibody; and (4) a step of collecting the cells after culture.Type: GrantFiled: October 7, 2016Date of Patent: December 6, 2022Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEMInventors: Nobuhiro Nishio, Yozo Nakazawa, Miyuki Tanaka, Daisuke Morita, Yoshiyuki Takahashi
-
Patent number: 11512139Abstract: The present invention provides a chimeric antigen receptor (CAR), comprising an extracellular part, at least one intracellular signaling domain, and at least one transmembrane domain, wherein the extracellular part of said CAR comprises a) at least one antigen binding domain, and b) at least one cytokine receptor activating or blocking domain. The invention also provides isolated nucleic acid molecule(s) encoding for the said CAR, a cell comprising said nucleic acid molecule(s), a cell expressing said CAR and therapeutic uses of said CAR.Type: GrantFiled: December 20, 2016Date of Patent: November 29, 2022Assignee: Miltenyi Biotec B.V. & Co. KGInventors: Hinrich Abken, Andreas Hombach
-
Patent number: 11497773Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.Type: GrantFiled: October 4, 2021Date of Patent: November 15, 2022Assignee: CRISPR THERAPEUTICS AGInventors: Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
-
Patent number: 11497791Abstract: Described herein are compositions and methods of using placental stem cell recruiting factors, more specifically, isolated placental stem cell recruiting factors. In one embodiment, isolated placental stem cell recruiting factors are delivered to a site such as a diseased or injured organ and/or body part in an amount sufficient to recruit stem cells to the site.Type: GrantFiled: February 18, 2019Date of Patent: November 15, 2022Assignee: MiMedx Group, Inc.Inventors: Thomas J. Koob, Rebeccah J. C. Brown
-
Patent number: 11473105Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.Type: GrantFiled: May 11, 2017Date of Patent: October 18, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Kerstin Wunderlich, Jort Vellinga
-
Patent number: 11471487Abstract: The present invention includes a method for expanding a population of electroporated T cells. The method includes electroporating a population of cells comprising T cells with mRNA encoding a chimeric membrane protein comprising an antigen binding domain to a molecule and an intracellular domain of a co-stimulatory molecule, wherein the cultured T cells expand at least 10 fold. The invention further includes an expanded population of T cells, compositions comprising the cells and methods of treatment.Type: GrantFiled: October 30, 2015Date of Patent: October 18, 2022Assignee: The Trustees of the University of PennsylvaniaInventors: Yangbing Zhao, Xiaojun Liu, Carl H. June
-
Patent number: 11471420Abstract: Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.Type: GrantFiled: March 22, 2021Date of Patent: October 18, 2022Assignee: Coastar Therapeutics Inc.Inventor: Eddie Yocon Chung
-
Patent number: 11471491Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.Type: GrantFiled: October 1, 2021Date of Patent: October 18, 2022Assignee: CRISPR THERAPEUTICS AGInventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
-
Patent number: 11471453Abstract: A method for modulating an immune response by activating or inhibiting dopaminergic neurons in the Ventral Tegmental Area (VTA) is provided. Modulation is achieved by modulating the activity, the abundance or both of: a natural killer cell, a CD8 T-cell, a CD4 T-cell, a B-cell, a dendritic cell, a macrophage, a granulocyte, or their combination.Type: GrantFiled: March 30, 2020Date of Patent: October 18, 2022Assignees: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, HEALTH CORPORATION - RAMBAMInventors: Asya Rolls, Tamar Ben Shannan, Hilla Azulay-Debbie, Fahed Hakim, Maya Schiller, Shai Shen-Orr, Elina Starosvetsky
-
Patent number: 11464806Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.Type: GrantFiled: January 28, 2020Date of Patent: October 11, 2022Assignee: JUNCTUCELL BIOMED MANUFACTURING GMBHInventors: Christine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
-
Patent number: 11459567Abstract: The present invention generally relates to the field of molecular biology and RNA interference (RNAi). More specifically, the present invention relates to specific siRNA molecules, compositions and uses thereof, as well as methods of treating cancer and methods of inhibiting cancer cell proliferation, particularly methods of treating breast cancer. Yet more particularly, the methods of the present invention are methods for inhibiting growth of triple negative breast cancer (TNBC). In a preferred embodiment, the invention provides specific siRNA molecules, comprising a sequence selected from SEQ ID NO: 1 and SEQ ID NO: 2, and from any other sequence having a sequence identity greater than 90% between the siRNA and the portion of the target gene. Such siRNA molecules are suitable for the treatment of breast cancer, particularly, TNBC.Type: GrantFiled: June 24, 2020Date of Patent: October 4, 2022Inventor: Patricia Virginia Elizalde
-
Patent number: 11458168Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.Type: GrantFiled: May 23, 2018Date of Patent: October 4, 2022Assignee: Baylor College of MedicineInventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian